SCHEMBL25834824

SCHEMBL25834824

CC(C)Sc1nnc(-c2ccc(C(=O)C(C)C)cc2)o1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 2/20 0.52
TSHR P16473 3/20 0.49
POLB P06746 3/20 0.49
ALDH1A1 P00352 4/20 0.47
NPC1 O15118 5/20 0.45
RAB9A P51151 5/20 0.45
PKM P14618 2/20 0.45
KDM4E B2RXH2 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP2D6 P10635 1/20 0.43
CYP2C9 P11712 1/20 0.43
HPGD P15428 1/20 0.43
CYP2C19 P33261 1/20 0.43
PPARG P37231 1/20 0.43
HSD17B10 Q99714 1/20 0.43
RXFP1 Q9HBX9 1/20 0.43
NCOR2 Q9Y618 1/20 0.43
MAPT P10636 5/20 0.43
MEN1 O00255 1/20 0.42
ALOX15 P16050 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25851787 0.83 CYP1A2 (0.57) TP53TSHRPOLBALDH1A1NPC1
SCHEMBL25836975 0.82 ALDH1A1 (0.48) TP53TSHRPOLBALDH1A1NPC1
SCHEMBL23782650 0.79 NPC1 (0.68) TP53TSHRPOLBALDH1A1NPC1
SCHEMBL25834961 0.78 NPC1 (0.45) TP53TSHRPOLBALDH1A1NPC1
SCHEMBL20622932 0.77 NPC1 (0.50) TP53TSHRPOLBALDH1A1NPC1
SCHEMBL25856877 0.75 HDAC8 (0.46) POLBALDH1A1NPC1RAB9AMAPT
SCHEMBL25835003 0.74 NOTUM (0.46) POLBALDH1A1NPC1RAB9AKDM4E
SCHEMBL15452607 0.73 TP53 (0.51) TP53TSHRPOLBALDH1A1NPC1
SCHEMBL25836397 0.73 KMT2A (0.51) TP53TSHRPOLBALDH1A1NPC1
SCHEMBL25851756 0.72 TP53 (0.50) TP53TSHRPOLBALDH1A1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230265429-A1 SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF Arrowhead Pharmaceuticals, Inc. 2023-08-24 US disclosed
US-20230265429-A1 SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF Arrowhead Pharmaceuticals, Inc. 2023-08-24 US disclosed
US-20230226193-A1 LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS Arrowhead Pharmaceuticals, Inc. 2023-07-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230226193-A1 LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS CPT1B, MUSK, MYLK2 TP53 4012/4885TSHR 1324/4885POLB 302/4885
US-20230265429-A1 SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF MUSK, MYLK2, TNNC1 TP53 4218/4885TSHR 1489/4885POLB 2117/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.